Pritumumab
| Pritumumab?
| |
| Therapeutic monoclonal antibody | |
| Source | Human |
| Target | ? |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
|
WikiDoc Resources for Pritumumab | |
|
Articles | |
|---|---|
|
Most recent articles on Pritumumab | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Pritumumab at Clinical Trials.gov Clinical Trials on Pritumumab at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Pritumumab
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Pritumumab Discussion groups on Pritumumab Patient Handouts on Pritumumab Directions to Hospitals Treating Pritumumab Risk calculators and risk factors for Pritumumab
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Pritumumab | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Pritumumab is a human monoclonal antibody and which it is used to treat cancer.
Human monoclonal antibodies ("-u-") | |
|---|---|
| "-limu-" (immune system) | immunosuppression: Adalimumab, Atorolimumab, Gantenerumab, Golimumab, Lerdelimumab, Metelimumab, Morolimumab, Ziralimumab
immune activation: Ipilimumab, Tremelimumab other: Bertilimumab |
| "-kinu-" (interleukin as target) | Canakinumab |
| "-tumu-" (cancer immunotherapy) | Adecatumumab, Anetumumab, Belimumab, Duntumumab, Iratumumab, Lexatumumab, Lucatumumab, Mapatumumab, Ofatumumab, Panitumumab, Pritumumab, Votumumab, Zalutumumab, Zanolimumab |
| "-osu-" (bone) | Denosumab |
| "-mulu-" (musculoskeletal) | Durimulumab, Durmulumab, Stamulumab |
| "-fungu-" (fungal) | Efungumab |
| "-viru-" (viral) | Exbivirumab, Libivirumab, Regavirumab, Sevirumab, Tuvirumab |
| "-bacu-" (bacterial) | Nebacumab, Raxibacumab |
WikiDoc Research Resources for Pritumumab | |
|---|---|
| Articles on Pritumumab | Most recent articles on Pritumumab • Most cited articles on Pritumumab • Review articles on Pritumumab • Articles on Pritumumab in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on Pritumumab | Powerpoint slides on Pritumumab • Images of Pritumumab • Photos of Pritumumab • Podcasts & MP3s on Pritumumab • Videos on Pritumumab |
| Evidence Based Medicine Regarding Pritumumab | AND (Cochrane Database Syst Rev[http://worldselectshop.com/?id=9361 Cochrane Collaboration on Pritumumab • Bandolier on Pritumumab • TRIP on Pritumumab |
| Cost Effectiveness of Pritumumab | AND (Cost effectiveness) |
| group5 = Clinical Trials Involving Pritumumab | list5 = Ongoing Trials on Pritumumab at Clinical Trials.gov • Trial results on Pritumumab • Clinical Trials on Pritumumab at Google
| group6 = Guidelines / Policies / Government Resources (FDA/CDC) Regarding Pritumumab
| list6 = US National Guidelines Clearinghouse on Pritumumab • NICE Guidance on Pritumumab • NHS PRODIGY Guidance • FDA on Pritumumab • CDC on Pritumumab
| group7 = Textbook Information on Pritumumab
| list7 = Books and Textbook Information on Pritumumab
| group8 = Pharmacology Resources on Pritumumab
| list8 =
AND (Dose)}} Dosing of Pritumumab • AND (drug interactions)}} Drug interactions with Pritumumab • AND (side effects)}} Side effects of Pritumumab • AND (Allergy)}} Allergic reactions to Pritumumab • AND (overdose)}} Overdose information on Pritumumab • AND (carcinogenicity)}} Carcinogenicity information on Pritumumab • AND (pregnancy)}} Pritumumab in pregnancy • AND (pharmacokinetics)}} Pharmacokinetics of Pritumumab •
| group9 = Genetics, Pharmacogenomics, and Proteinomics of Pritumumab
| list9 =
AND (pharmacogenomics)}} Genetics of Pritumumab • AND (pharmacogenomics)}} Pharmacogenomics of Pritumumab • AND (proteomics)}} Proteomics of Pritumumab
| group10 = Newstories on Pritumumab
| list10 = Pritumumab in the news • Be alerted to news on Pritumumab • News trends on Pritumumab</small>
| group11 = Commentary on Pritumumab
| list11 =
Blogs on Pritumumab
| group12 = Patient Resources on Pritumumab | list12 = Patient resources on Pritumumab • Discussion groups on Pritumumab • Patient Handouts on Pritumumab • Directions to Hospitals Treating Pritumumab • Risk calculators and risk factors for Pritumumab
| group13 = Healthcare Provider Resources on Pritumumab
| list13 =
Symptoms of Pritumumab • Causes & Risk Factors for Pritumumab • Diagnostic studies for Pritumumab • Treatment of Pritumumab
| group14 = Continuing Medical Education (CME) Programs on Pritumumab | list14 = CME Programs on Pritumumab
| group15 = International Resources on Pritumumab | list15 = Pritumumab en Espanol • Pritumumab en Francais
| group16 = Business Resources on Pritumumab | list16 = Pritumumab in the Marketplace • Patents on Pritumumab
| group17 = Informatics Resources on Pritumumab | list17 = List of terms related to Pritumumab
}}
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies